Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | OGA | O60502 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115059 | 1.00 | CYP2D6 (0.44) | CYP2D6LTA4HOPRD1MC4RHRH3 | |
| SCHEMBL136842 | 0.89 | LTA4H (0.42) | CYP2D6LTA4HOPRD1MC4RHRH3 | |
| SCHEMBL13372595 | 0.89 | LTA4H (0.42) | CYP2D6LTA4HOPRD1MC4RHRH3 | |
| SCHEMBL136843 | 0.89 | LTA4H (0.42) | CYP2D6LTA4HOPRD1MC4RHRH3 | |
| SCHEMBL2602809 | 0.87 | CYP2D6 (0.54) | CYP2D6LTA4HOPRD1MC4ROPRM1 | |
| SCHEMBL2605879 | 0.85 | CYP2D6 (0.49) | CYP2D6LTA4HOPRD1MC4ROPRM1 | |
| SCHEMBL2115070 | 0.84 | CYP2D6 (0.47) | CYP2D6LTA4HOPRD1MC4ROPRM1 | |
| SCHEMBL2602805 | 0.81 | CYP2D6 (0.44) | CYP2D6LTA4HOPRD1MC4ROPRM1 | |
| SCHEMBL2119158 | 0.81 | LTA4H (0.49) | CYP2D6LTA4HOPRD1MC4ROPRM1 | |
| SCHEMBL2602808 | 0.81 | LTA4H (0.42) | CYP2D6LTA4HOPRD1MC4ROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
| EP-2414349-A1 | 3-Ý1,4¨OXAZEPANE-4-PYRIMIDONE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114179-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | PSEN1, MAPT, PSEN2 | CYP2D6 2595/4885LTA4H 4183/4885OPRD1 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.